J
Julian Mustroph
Researcher at University Hospital Regensburg
Publications - 31
Citations - 714
Julian Mustroph is an academic researcher from University Hospital Regensburg. The author has contributed to research in topics: Ca2+/calmodulin-dependent protein kinase & Medicine. The author has an hindex of 11, co-authored 27 publications receiving 411 citations. Previous affiliations of Julian Mustroph include University of Regensburg.
Papers
More filters
Journal ArticleDOI
Empagliflozin directly improves diastolic function in human heart failure
Steffen Pabel,Steffen Pabel,Stefan Wagner,Hannah Bollenberg,Philipp Bengel,Árpád Kovács,Christian Schach,P Tirilomis,Julian Mustroph,André Renner,Jan Gummert,Thomas H. Fischer,Sophie Van Linthout,Carsten Tschöpe,Katrin Streckfuss-Bömeke,Gerd Hasenfuss,Lars S. Maier,Nazha Hamdani,Samuel Sossalla,Samuel Sossalla +19 more
TL;DR: This study aims to investigate whether empagliflozin may cause direct pleiotropic effects on the myocardium, and if so, what mechanisms cause these effects and how they are distributed.
Journal ArticleDOI
Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes.
Julian Mustroph,Olivia Wagemann,Charlotte M. Lücht,Maximilian Trum,Karin P. Hammer,Can Martin Sag,Simon Lebek,Daniel Tarnowski,Jörg Reinders,Filippo Perbellini,Cesare M. Terracciano,Christof Schmid,Simon Schopka,Michael Hilker,York Zausig,Steffen Pabel,Samuel Sossalla,Frank Schweda,Lars S. Maier,Stefan Wagner +19 more
TL;DR: This study tested whether empagliflozin reduces CaMKII‐ activity and improves Ca2+‐handling in human and murine ventricular myocytes and showed reduced mortality and hospitalization due to heart failure in diabetic patients treated with emPaglif lozin.
Journal ArticleDOI
CaMKII as a target for arrhythmia suppression.
TL;DR: Both inhibition of CaMKII itself to prevent arrhythmias, as well as anti-arrhythmic approaches affecting CaMK II activity via alterations in signaling cascades upstream and downstream of Ca MKII will be discussed.
Journal ArticleDOI
Improvement of cardiomyocyte function by a novel pyrimidine-based CaMKII-inhibitor
Stefan Neef,Alexander Steffens,Patricia Pellicena,Julian Mustroph,Simon Lebek,Katharina Ort,Howard Schulman,Lars S. Maier +7 more
TL;DR: AS105 is a novel, highly potent ATP-competitive CaMKII inhibitor that effectively reduced SR Ca2+-leak, thus improving SR Ca 2+-accumulation and reducing cellular arrhythmogenic correlates, without negatively influencing excitation-contraction coupling.
Journal ArticleDOI
The novel CaMKII inhibitor GS-680 reduces diastolic SR Ca leak and prevents CaMKII-dependent pro-arrhythmic activity.
Simon Lebek,A. Plößl,Maria J. Baier,Julian Mustroph,D Tarnowski,Charlotte M. Lücht,Simon Schopka,B. Flörchinger,Christof Schmid,York Zausig,N. Pagratis,B. Marchand,Dmitry Koltun,W.K. Hung,Shekeba Ahmadyar,Luiz Belardinelli,Lars S. Maier,Stefan Wagner +17 more
TL;DR: The novel ATP-competitive and selective CaMKII inhibitor GS-680 inhibits pro-arrhythmic activity in human atrium and improves contractility in failing human ventricle, which may have therapeutic implications.